Publications by authors named "T Warnecke"
Background: Pallidal neurostimulation is an effective treatment for severe isolated dystonia, but long-term data from clinical trials are lacking.
Objectives: To evaluate long-term efficacy and safety of pallidal neurostimulation in patients with isolated generalized or segmental dystonia.
Methods: Extension study of the prospective multicenter trial (n = 40; July 2002 to May 2004), all patients received effective stimulation and underwent regular follow-up.
Background: Patients with Progressive Supranuclear Palsy (PSP) suffer from several neuropsychological impairments. These mainly affect the frontal lobe and subcortical brain structures. However, a scale for the assessment of cognitive and neuropsychiatric disability in PSP is still missing.
View Article and Find Full Text PDFThe lack of patient and public involvement in oropharyngeal dysphagia (OD) intervention studies in Parkinson's disease (PD) can bias the choice of outcomes to be measured in these studies. This study aimed to obtain perspectives of individuals living with OD in PD and family members/caregivers on OD intervention outcomes that are important to them. This is part of a larger Core Outcome Set project.
View Article and Find Full Text PDFArticle Synopsis
- Dysphagia, a serious swallowing disorder, is common in patients with advanced Parkinson's disease (PD) and doesn’t improve with standard treatments.
- This study tested whether combining stimulation of the subthalamic nucleus (STN) and substantia nigra pars reticulata (SNr) could enhance swallowing function in 20 PD patients undergoing deep brain stimulation (DBS).
- Results showed no significant difference in swallowing improvements between the two stimulation methods, but overall, all patients experienced better outcomes over eight weeks, likely due to ongoing swallowing therapy and increased focus on their swallowing abilities.
Disease-modifying therapeutics in the α-synucleinopathies multiple system atrophy (MSA) and Parkinson's Disease (PD) are in early phases of clinical testing. Involving patients' preferences including therapy-associated risk willingness in initial stages of therapy development has been increasingly pursued in regulatory approval processes. In our study with 49 MSA and 38 PD patients, therapy-associated risk willingness was quantified using validated standard gamble scenarios for varying severities of potential drug or surgical side effects.
View Article and Find Full Text PDF